CD4 and neoplasm: While traditionally recognized for their ability to prime CD4+ T helper cells that support cytotoxic T cell responses against cancer, recent research highlights a dual capacity of cDC2s: they can also contribute to the induction and maintenance of regulatory T cells (Tregs), thereby potentially suppressing anti-tumor immunity.